Amgen to Review Benefits, Risks of ESA Therapy in Chronic Renal Failure Patients at FDA Advisory Committee. Company Recommends Hemoglobin Target of 10-12 g/dL as Risk Management Approach.

This article is part of a special supplement published by Nephrology News & Issues in the February 2014 issue entitled, "Iron therapy and a quarter century of ESAs: What have we learned?"; The ...

Resistance to ESA therapy can occur in patients with malnutrition, folate or vitamin B 12 deficiency, secondary hyperparathyroidism, hemolysis, hemoglobinopathies, or primary bone marrow disorders ...

LOS ANGELES, March 30, 2017 /PRNewswire-iReach/ -- Therapy Pet has been operating in the animal assisted therapy niche for several years now. The organization focuses primarily on helping people ...

ESA doses during the 6 months before the inclusion of roxadustat were maintained at the level between 9000 and 12 000 IU/week (129.5 and 244.9 IU/kg/week). At the time of roxadustat therapy initiation ...

Marie Chacon - Marie Chacon - ESA Letters, Marriage & Family Therapist, Los Angeles, CA, 90045, (661) 689-7912, My approach to therapy is to provide a supportive environment for change through ...